Korea / KHIDI President Talks Domestic Vaccine R&D
KHIDI’s Soonman KWON outlines the public health R&D funding landscape in Korea, plans to increase Korea’s capacity to develop and produce its own vaccines in the wake of the COVID-19…
Korea Health Industry Development Institute (KHIDI) is a government-affiliated institution which performs professional and systematic support to develop domestic health industry and enhance health services.
Since its establishment in 1999, KHIDI has led expansion of healthcare R&D investment and building competitiveness of Korea’s healthcare industry, i.e., health services, pharmaceuticals, medical devices, food and beauty-cosmetic. We are also witnessing rapid growth of global healthcare sector – especially in attracting foreign patients and exporting healthcare service providers along with healthcare systems. This is a valuable outcome we have earned through years of efforts on global advancement and outreach in this sector.Since its establishment in 1999, KHIDI has been playing a major role in the industry development as the nation’s only one organization responsible for fostering health industry. While we have striven to produce more successful research outcomes by means of greater investments in Health Technology (HT) R&D, KHIDI also took the initiative in increasing competitiveness in different areas of health industry, including pharmaceuticals, medical devices, foods, and beauty & cosmetics businesses.
Contact details:
Address: 187 Osongsaengmyeong2(i)-ro, Gangoe-myeon, Cheongwon-gun, Chungcheongbuk-do, 363-951 Korea
Tel: +82-43-713-8000 ~ 8005
KHIDI’s Soonman KWON outlines the public health R&D funding landscape in Korea, plans to increase Korea’s capacity to develop and produce its own vaccines in the wake of the COVID-19…
Despite its ageing population and growing need for healthcare, South Korea had just 2.6 doctors per 1,000 inhabitants in 2022, one of the lowest numbers among developed nations. To deal…
The latest pharma and healthcare news from APAC, including Celltrion’s plans to sell its Takeda portfolio to CBC; reforms to the South Korean national insurance system that may lead to…
Global medtech giant Medtronic is hoping that its latest acquisition – EOFlow, a South Korean wearable insulin patch maker – will enhance its competitiveness in the global diabetes market. …
A roundup of some of the most important recent stories from the burgeoning South Korean pharma and biotech industry, including a government plan to expand collaboration with the global innovation…
As big pharma continues to sharpen its focus on R&D by outsourcing other elements of the supply chain, including manufacturing, CDMOs have thrived. Samsung Biologics, one of the world’s top…
After launching the first Korean COVID-19 vaccine, SKYCovione, SK Bioscience is preparing for its next big milestone, a US subsidiary, with the appointment of two new executives who are already…
SK Bioscience’s announcement that the first batch of its domestically developed COVID vaccine has been shipped may mark a significant milestone in South Korea’s journey towards greater vaccine self-sufficiency. …
ExoCoBio’s CEO, Byong Seung Cho, went from biotech venture capital to setting up ExoCoBio, a company whose core technology is based on adipose stem-cell derived exosomes for regenerative medicine and…
South Korea has carved a place for itself as a dominant player in the global pharma and med-tech manufacturing industry with national companies Samsung Biologics and Celltrion leading the way.…
After a dynamic two years as CEO of Samsung Biologics, John Rim highlights some of the fundamentals behind the company’s rapid growth as a CDMO, including the creation of huge…
Stephen Yoo highlights the pioneering work that STCube Pharmaceuticals – a US subsidiary of Korean firm STCube – is undertaking in the immuno-oncology field, its three technology platforms, partnership approach,…
Founder and CEO of GeneMedicine, Dr Chae-Ok Yun, explains how the company, specialised in oncolytic virus development, has progressed since we last interviewed her two years ago, with one of…
See our Cookie Privacy Policy Here